WO2002044128A2 - Analogues de salicylate utilises en tant qu'antagonistes d'interleukine-4 - Google Patents

Analogues de salicylate utilises en tant qu'antagonistes d'interleukine-4 Download PDF

Info

Publication number
WO2002044128A2
WO2002044128A2 PCT/US2001/044643 US0144643W WO0244128A2 WO 2002044128 A2 WO2002044128 A2 WO 2002044128A2 US 0144643 W US0144643 W US 0144643W WO 0244128 A2 WO0244128 A2 WO 0244128A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
group
chr
hydrogen
alkyl
Prior art date
Application number
PCT/US2001/044643
Other languages
English (en)
Other versions
WO2002044128A3 (fr
Inventor
Kenneth J. Barr
Brian C. Cunningham
William Michael Flanagan
Wanli Lu
Brian C. Raimundo
Nathan D. Waal
Jennifer Wilkinson
Jiang Zhu
Wenjin Yang
Original Assignee
Sunesis Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunesis Pharmaceuticals, Inc. filed Critical Sunesis Pharmaceuticals, Inc.
Priority to AU2002219920A priority Critical patent/AU2002219920A1/en
Publication of WO2002044128A2 publication Critical patent/WO2002044128A2/fr
Publication of WO2002044128A3 publication Critical patent/WO2002044128A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/19—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups having unsaturation outside the aromatic ring

Definitions

  • This invention relates to antagonists of interleukin-4 signaling.
  • this invention relates to certain salicylate analogs that antagonize interleukin-4 signaling, to methods of making them, to pharmaceutical compositions containing them, and to their uses.
  • Interleukin-4 is a pleiotropic cytokine that is produced primarily by T helper type 2 lymphocytes (TH2 cells). The most clinically significant activity of this cytokine is the stimulation of immunoglobin class switching of the immune system's B-cells to IgE production. See P. Chomarat et al., "An update on interleukin-4 and its receptor", Eur.
  • antagonism of IL-4 can alleviate allergic responses. These include the correlation of allergy and asthma symptoms with IL-4 levels in both allergen immunotherapy and asthma patients, the reduction of spontaneous IgE production in lymphocytes following treatment with IL-4 antibodies, and the inability to induce asthma- associated eosinophilia in IL-4 gene knockout mice. Additional evidence exists correlating elevated levels of IL-4 with osteoporosis, osteoarthritis, rheumatoid arthritis, and autoimmune and other inflammation related disorders. Antagonism of IL-4 might further prove useful for therapeutically desirable immunosuppression.
  • Small molecule IL-1 antagonists have been sought. See R. Sarabu, "Design and synthesis of small molecule interleukin-1 receptor antagonists based on a benzene template, Drug Design Discovery, 15, 191-198 (1998).
  • this invention provides compounds of formula I compound of formula I:
  • each R is independently selected from the group consisting of hydrogen, hydroxy, alkyl, haloalkyl, aminoalkyl, guanidinoalkyl, alkoxy, amino, alkylamino, dialkylamino, cycloamino, alkylcarbonylamino, guanidino, carboxy, alkoxycarbonyl, and tetrazolyl; each R ⁇ is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, carboxy, and alkoxycarbonyl; each R is independently selected from the group consisting of alkyl and C 0 .
  • R 2 is selected from the group consisting of hydrogen, halo and hydroxy
  • R 4 is selected from the group consisting of hydrogen, hydroxy, amino, alkylamino, dialkylamino, and cycloamino;
  • R 5 is selected from the group consisting of hydrogen, halo, alkyl, haloalkyl, alkoxy, amino, alkylcarbonylamino, alkylsulfonylamino, benzenesulfonylamino, toluenesulfonylamino, carboxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloaminocarbonyl, and alkoxycarbonyl, or is R 3 ;
  • R 8 , R 9 , R 11 , and R 12 are independently selected from the group consisting of hydrogen, halo, alkyl, haloalkyl, methoxy, and ethoxy;
  • this invention provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of at least one compound of this invention.
  • These compositions find particular use as anti-asthmatic and anti-allergenic agents; and in the treatment of osteoporosis, osteoarthritis, rheumatoid arthritis, and autoimmune and other inflammation related disorders, and for therapeutically desirable immunosuppression.
  • this invention provides a method of treating an animal having a disease capable of treatment by administration of an IL-4 antagonist, comprising administration to that animal of a therapeutically effective amount of at least one compound of this invention, optionally in conjunction with at least one other conventional therapeutic agent for the disease being treated.
  • this invention provides methods of preparing the compounds of this mvention.
  • Alkyl means a linear monovalent hydrocarbyl group having 1 to 5 carbon atoms, or a branched or cyclic hydrocarbyl group having 3 to 5 carbon atoms. Exemplary alkyl groups include methyl, ethyl, isopropyl, cyclopropyl, tert-butyl, cyclopropylmethyl, and pentyl.
  • Alkoxy means the group -O-alkyl, where "alkyl” is as defined immediately before.
  • Carboxylate isosteres means those moieties that are members of R 3 as listed above in the Summary of the Invention except carboxylate itself. Such carboxylate isosteres are well known to persons of ordinary skill in the art and are used when an acidic moiety is desired.
  • Cycloalkylene means a cyclic hydrocarbyl group having 5 to 7 ring carbon atoms, bonded to an aryl group or other linker atom at both of two adjacent ring carbon atoms; such as 1,2-cyclohexylene. "Cycloalkylene also includes those compounds where the bond between the ring carbon atoms that are bonded to the aryl groups or other linker atoms is a double bond.
  • Cycloalkylene specifically includes cyclic compounds as defined immediately before where 1 or 2 of the ring carbon atoms are replaced by O, S, NH, or N- alkyl; such as 2,3-piperidinylene and 3,4-tetrahydropyranylene.
  • Cycloamino means a cyclic amino group having 5 to 7 ring atoms of which at least one is nitrogen and the remainder may all be carbon (e.g. pyrrolidino, piperidino) or one carbon may be replaced by O, S, NH, or N-alkyl (e.g. morpholino, piperazino, and the like).
  • Animal includes humans and non-human mammals, such as companion animals (cats, dogs, and the like) and farm animals (cattle, horses, sheep, goats, swine, and the like).
  • Disease includes any unhealthy condition of an animal, including particularly asthma, allergies, osteoporosis, osteoarthritis, rheumatoid arthritis, and autoimmune and other inflammation related disorders.
  • Halogen means fluorine, chlorine, or bromine; and “halo” likewise means fluoro, chloro, or bromo.
  • Haloalkyl means alkyl (as that term is defined above) substituted with 1 to 5 halogen atoms, especially fluorine or chlorine atoms.
  • Optionally fluorinated methoxy and “optionally fluorinated ethoxy” mean a methoxy group substituted with 0-3 fluorine atoms and an ethoxy group substituted with 0-5 fluorine atoms respectively.
  • “Pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and desirable, and includes excipients that are acceptable for veterinary use as well as for human pharmaceutical use. Such excipients may be solid, liquid, semisolid, or, in the case of an aerosol composition, gaseous.
  • “Pharmaceutically acceptable salts” means salts that are pharmaceutically acceptable and have the desired pharmacological properties. Such salts include salts that may be formed where acidic protons present in the compounds are capable of reacting with inorganic or organic bases. Suitable inorganic salts include those formed with the alkali metals, e.g. sodium and potassium, magnesium, calcium, and aluminum.
  • Suitable organic salts include those formed with organic bases such as the amine bases, e.g. ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. Such salts also include acid addition salts formed with inorganic acids (e.g. hydrochloric and hydrobromic acids) and organic acids (e.g. acetic acid, citric acid, maleic acid, and the alkane- and arene-sulfonic acids such as methanesulfonic acid and benzenesulfonic acid). When there are two acidic groups present, a pharmaceutically acceptable salt may be a mono-acid-mono-salt or a di-salt; and similarly where there are more than two acidic groups present, some or all of such groups can be salified.
  • organic bases such as the amine bases, e.g. ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.
  • Such salts also include acid
  • a "protecting group” has the meaning conventionally associated with it in organic synthesis, i.e. a group that selectively blocks one or more reactive sites in a multifunctional compound such that a chemical reaction can be carried out selectively on another unprotected reactive site and such that the group can readily be removed after the selective reaction is complete.
  • a “therapeutically effective amount” means the amount that, when administered to an animal for treating a disease, is sufficient to effect treatment for that disease.
  • Treating" or “treatment” of a disease includes preventing the disease from occurring in an animal that may be predisposed to the disease but does not yet experience or exhibit symptoms of the disease (prophylactic treatment), inhibiting the disease (slowing or arresting its development), providing relief from the symptoms or side-effects of the disease (including palliative treatment), and relieving the disease (causing regression of the disease).
  • the compounds of this invention may possess one or more chiral centers or olefinic bonds, and, if they do, can therefore be produced as individual stereoisomers or as mixtures of stereoisomers, depending on whether individual stereoisomers or mixtures of stereoisomers of the starting materials are used. Unless indicated otherwise, the description or naming of a compound or group of compounds is intended to include both the individual stereoisomers or mixtures (racemic or otherwise) of stereoisomers. Methods for the determination of stereochemistry and the separation of stereoisomers are well known to a person of ordinary skill in the art [see the discussion in Chapter 4 of J. March, "Advanced Organic Chemistry", 4th ed., John Wiley and Sons, New York, NY, 1992].
  • Implicit hydrogen atoms are omitted from the formulae for clarity, but should be understood to be present.
  • Presently preferred compounds of the invention are those where one or more of the following conditions are met:
  • X and Y are independently absent or are -CHR X -, provided that at least one of X and Y is present; (2) R 3 is carboxy;
  • R 4 is hydrogen or hydroxy, especially hydroxy
  • R 2 , R 8 , and R 9 are hydrogen
  • R 16 , R 17 , and R 18 are independently hydrogen, fluorine, or trifluoromethyl, preferably where at least R 16 is not hydrogen; and the pharmaceutically acceptable salts thereof.
  • More preferred compounds are those where two or more of the above preferences are met.
  • the compounds of this invention are antagonists of IL-4 signaling.
  • Their activity as IL-4 signaling antagonists in vitro can be measured by methods such as the STAT6 phosphorylation assay discussed in J. Hon et al., Science, 265, 1701-1706 (1994), F. W. Jo et al., Mol. Cell Biol, 15, 3336-3343 (1995), and K. Takeda et al., Nature, 380, 627- 630 (1996); and as discussed in Example 3.
  • Their activity can be measured in vivo by activity in the cynomolgus monkey primate model described in CD.
  • the therapeutic ratio of a compound can be determined, for example, by comparing the dose that gives effective anti-asthmatic or anti-allergic activity in a suitable in vivo model such as the cynomolgus model described in Wegner et al., with the dose that gives significant weight loss (or other observable side-effects) in the test animal species.
  • compositions and administration in therapeutically effective amounts by any of the usual modes known in the art, either singly or in combination with at least one other compound of this invention and/or at least one other conventional therapeutic agent for the disease being treated.
  • a therapeutically effective amount may vary widely depending on the disease, its severity, the age and relative health of the animal being treated, the potency of the compound(s), and other factors.
  • Therapeutically effective amounts of compounds of this invention may range from approximately 0.01-100 mg/Kg body weight.
  • a person of ordinary skill in the art will be able without undue experimentation, having regard to that skill and this disclosure, to determine a therapeutically effective amount of a compound of this invention for a given disease.
  • compositions will be administered as pharmaceutical compositions by one of the following routes: oral, topical, systemic (e.g. transdermal, intranasal, by inhalation, or by suppository), or parenteral (e.g. intramuscular, subcutaneous, or intravenous injection).
  • routes e.g. oral, topical, systemic (e.g. transdermal, intranasal, by inhalation, or by suppository), or parenteral (e.g. intramuscular, subcutaneous, or intravenous injection).
  • Compositions may take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions; and comprise at least one compound of this invention in combination with at least one pharmaceutically acceptable excipient. Suitable excipients are well known to persons of ordinary skill in the art, and they, and the methods of formulating the compositions, may be found in such standard references as A.R.
  • liquid carriers especially for injectable solutions, include water, aqueous saline solution, aqueous dextrose solution, and glycols.
  • compounds of this invention will be administered orally, by inhalation (especially for asthma and in pulmonary inflammatory conditions), or topically (especially for psoriasis).
  • the amount of a compound of this invention in the composition may vary widely depending on the type of composition, size of a unit dosage, kind of excipients, and other factors well known to those of ordinary skill in the art.
  • the final composition may comprise from 0.0001 percent by weight (%w) to 10 %w of the compound of this invention, preferably 0.001 %w to 1 %w, with the remainder being the excipient or excipients.
  • a composition may optionally contain, in addition to a compound of this invention, at least one other compound of this invention, and/or at least one other agent for the disease state being treated.
  • the starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Company (Milwaukee, WI), Bachem (Torrance, CA), Sigma (St. Louis, MO), or are prepared by methods well known to a person of ordinary skill in the art following procedures described in such references as Fieser and Fieser's "Reagents for Organic Synthesis", vols. 1-17, John Wiley and Sons, New York, NY, 1991; Rodd's “Chemistry of Carbon Compounds", vols. 1-5 and supplements, Elsevier Science Publishers, 1989; "Organic Reactions", vols.
  • the starting materials, intermediates, and compounds of this invention may be isolated and purified using conventional techniques, including filtration, distillation, crystallization, chromatography, and the like. They may be characterized using conventional methods, including physical constants and spectral data.
  • an appropriately substituted biphenyl or biphenyl ether is reacted with an appropriately substituted benzene to form the linker -X-A-B-Y- between the biphenyl/biphenyl ether and the benzene.
  • the alkene-containing linker is readily prepared by the either of two methods.
  • a suitably substituted aryl aldehyde or ketone is reacted with the sodium salt of a suitably substituted triphenylphosphonium halide (Wittig reaction), prepared from the corresponding haloaryl compound.
  • a suitably substituted benzyltriphosphonium halide (prepared from the corresponding benzyl bromide) dissolved in a solvent such as tetrahydrofuran is treated with a solution of n-butyllithium at 0 °C, stirred at room temperature, then the suitably substituted biphenylaldehyde is added.
  • the aryl aldehyde or ketone may be commercially available or may be prepared by methods such as reduction of the corresponding carboxylic acid or oxidation of the corresponding alcohol.
  • the haloaryl analog may be available commercially, or may be synthesized by from the corresponding alcohol.
  • reaction is quenched with methanol, extracted, dried, and the extracts concentrated to yield the olefin-linked compound.
  • a suitably substituted aryl halide or triflate and a suitably substituted vinylarene (the Heck coupling reaction), arylboronic acid (the Suzuki coupling reaction), or aryl halide and aryl trialkyltin (the Stille coupling reaction) are reacted in the presence of a Pd catalyst.
  • Substituted analogs may be prepared analogously.
  • the alkyl linker is readily prepared by reduction of the corresponding alkene linker (see above) by any number of common reagents including H 2 (g) over Pd/C.
  • Substituted analogs of the alkyl linker may be prepared by a variety of means known to a person of ordinary skill in the art.
  • the ketone linkage (see below) may be alkylated at the site neighboring the ketone functional group by combination with an electrophile in the presence of base. The ketone functional group may be converted to an amino group by reductive amination.
  • the ketone linkage may also be converted to a substituted alkene linkage by reaction with the sodium salt of an appropriately substituted triphenylphosphonium halide reagent or similar.
  • the hydroxyl group of the . linkage sited as the precursor to the ketone may alternatively be converted to an ether or ester moiety by methods familiar to a person of ordinary skill in the art.
  • the ether linker may be prepared by any of three methods.
  • a suitably substituted aryl alcohol may be combined in the presence of base with an appropriately substituted halomethyl arene of the activated (e.g. mesylate or tosylate) ester of an appropriately substituted hydroxymethyl arene.
  • an appropriately substituted aryl alcohol may be combined with an appropriately substituted hydroxymethyl arene in the presence of triphenylphosphine and diethyl azodicarboxylate (the Mitsunobu reaction).
  • an appropriately substituted aryl halide may be combined with an appropriately substituted hydroxymethyl arene in the presence of sodium tert-butoxide and a Pd-based catalyst (Buchwald coupling conditions). Similar preparations afford linkers where R ⁇ is other than hydrogen.
  • the amide linker may be prepared by either of two methods.
  • a suitably substituted arylamine is combined with a suitably substituted arylcarboxyhc acid in the presence of one of a variety of condensation reagents known to a person of ordinary skill in the art, such as EDCI, HOBT, HATU, CDI, and the like.
  • a suitably substituted arylamine is combined with a suitably substituted activated arylcarboxyhc acid derivative, such as an arylcarboxyhc acid halide, under Weinreb conditions.
  • the thioether linkage may prepared by the combination of a suitably substituted arenethiol with a suitably substituted halomethyl arene or activated ester of a suitably substituted hydroxymethyl arene.
  • the sulfoxide linkage is prepared by single oxidation of the thioether linkage by any of a variety of mild oxidation reagents known to a person of ordinary skill in the art, such as metachloroperbenzoic acid.
  • the sulfone linkage is prepared from either the thioether or the sulfoxide by treatment with any of a variety of stronger oxidation reagents also known to a person of ordinary skill in the art, such as sodium periodate.
  • the sulfonamide linkage maybe prepared by reaction of a suitably substituted arylamine with a suitably substituted arenesulfonyl halide, which may in turn be first prepared from the appropriately substituted arenesulfonic acid by one of a variety of methods known to a person of ordinary skill in the art; or by alkylation of a suitably substituted aryl sulfonamide with an aryl halide in the presence of a base.
  • the ketone linkage is prepared by oxidation of the corresponding hydroxyl substituted linkage by the use of MnO or any other of a variety of oxidizing reagents known to a person of ordinary skill in the art.
  • the hydroxy substituted linkage can be prepared by reaction of a suitably substituted aryl aldehyde with a suitably substituted arylmagnesium halide, prepared in advance from the corresponding aryl halide (the Grignard reaction).
  • the cycloalkylene linkage containing a double bond between the bonding ring carbons may be prepared by the reaction of a 1,2-dihalocycloalkene sequentially with the appropriately substituted arylboronic acids (Suzuki coupling reaction) or aryl trialkyltin reagents (Stille coupling reaction) in the presence of a Pd catalyst.
  • the reduced cycloalkylene linkage may be prepared by reduction of the corresponding double-bonded linkage by reaction with H 2 (g) over Pd/C. hi large part the cycloalkylene linkages where there are hetero atom(s) in the ring may be prepared in the same manner.
  • the 2-hydroxypropyl linkage may be prepared by the reaction of a suitably substituted arylacetaldehyde with a suitably substituted arylmethylmagnesium halide, prepared from the corresponding arenylmethyl halide (the Grignard coupling reaction).
  • the amidomethyl linkage may be prepared by the reaction of a suitably substituted arenecarboxylic acid or activated arenecarboxylic acid derivative with an appropriately substituted aminomethylarene, under conditions described above for the A-B linked amide case.
  • the amidomethyl linkage may be prepared by the reaction of a suitably substituted areneacetic acid or activated areneacetic acid derivative with an appropriately substituted aminoarene, under the same conditions.
  • the C-O-C ether linkage may prepared by combination of the appropriately substituted hydroxymethyl arene with the appropriately substituted halomethyl-, methanesulfonyloxy-, or -toluenesulfonyloxymethyl arene in the presence of base; and similarly when -X-A-B-Y- is -CH 2 -CHR Y -O-CHR Y -.
  • biphenyl linkage may be formed either before or after the formation of the -X-A-B-Y- linkage.
  • the biaromatic moiety may be available commercially, or alternatively may be assembled either prior to or subsequent to the assembly of the -X-A- B-Y- linkage by reactions such as a coupling reaction between the appropriately substituted aryl halide or triflate and an arylboronic acid (Suzuki coupling reaction) or an aryltriphenyltin reagent (Stille coupling reaction) in the presence of a palladium catalyst.
  • phenyl rings may be substituted with substituents inert to the reaction conditions (or substituents protected against the reaction conditions associated with formation of the compound skeleton, where the protecting group can be removed without adverse effect on the remainder of the compound) without affecting the reactions described.
  • substituents for example, a carboxylic acid
  • it will typically be protected throughout the synthesis as an alkyl, e.g. C -t alkyl ester, typically the methyl ester; with the ester being removed in the final deprotection step by reaction with an aqueous base, such as aqueous lithium hydroxide.
  • a substituent When a substituent is or contains an amine or guanidino group, it will typically be protected with a typical amine-protecting group well known to a person of ordinary skill in the art, such as tert-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ), 9- fluorenylmethoxycarbonyl (FMOC), and the like, if needed, with the protecting group being removed in the final deprotection step by such methods as are conventional for removal of these amine-protecting groups.
  • a carboxylic acid may be protected as an ester that is differentially removable, i.e. removable under circumstances where other carboxyl groups remain protected.
  • a substituent When a substituent is a hydroxy group, it will typically be protected with a typical hydroxy-protecting group such as a tertiary silyl group, e.g. tert-butyldimethylsilyl.
  • a typical hydroxy-protecting group such as a tertiary silyl group, e.g. tert-butyldimethylsilyl.
  • suitable protecting groups for substituents during the syntheses will be within the skill of a person of ordinary skill in the art having regard to that skill and this disclosure.
  • a substituent when a substituent is a carboxylate isostere, it may be prepared either from an intermediate or product containing a carboxylate group (by conversion of the carboxylate group to the isostere) or through the use of a starting material containing a carboxylate isostere rather than a carboxylate group; and such materials and reactions are well known to a person of ordinary skill in the art having regard to that skill and appropriate reference documents.
  • SP724 was prepared in the same manner as was SP727 omitting the amine methylation steps.
  • DMSO-d 6 ⁇ 3.65 (s, 2 H), 3.80 (s, 3 H), 3.89 (s, 3 H), 7.22 (s, 1 H), 7.31 (s, 1 H).
  • LRMS 212 (M+l) + .
  • Ramos cells were grown in RPMI medium supplemented with 10% fetal bovine serum and antibiotics. Cells were split to 0.5 to 0.8 xlO 6 cells/mL on the day before the assay. On the day of the assay, the cell concentration is approximately lxlO 6 cells/mL.
  • the concentration of IL-4 used in the assay was determined by carrying out a dose- response curve according to the protocol detailed below. IL-4 concentrations between 0.25 and 0.5 ng/mL result in STAT6 activation that is in the linear range of the assay.
  • Compound testing was carried out in the absence of serum.
  • the samples made up as in the table (1 mL), were preincubated in 15 L polypropylene conical tubes (Corning) at 37 °C for 30 minutes.
  • the Ramos cell concentration was determined; and the cells were centrifuged at 800 x g at room temperature for 5 minutes. The cells were resuspended in pre-warmed RPMI medium (without serum) to a concentration of 10 x 10 6 cells/mL. To each sample (1 mL) was added 1 mL of the cell suspension; and the samples were incubated at 37 °C for 30 minutes.
  • Protein Extracts The samples were centrifuged at 800 x g at room temperature for 5 minutes. All medium was carefully removed from the cell pellet, which was placed on ice. The cells were then lysed with 50 ⁇ l of RIP A buffer containing protease and phosphatase inhibitors [150 mMNaCl, 50 ni Tris pH 8.0, 1.0% NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate, 10 ⁇ g/mL aprotinin, 10 ⁇ g/mL antipain, 5 ⁇ g/mL leupeptin, 1 mg/mL Pefablock SC, 50 MNaF, 80 mM sodium glycerophosphate, and 2 m sodium vanadate (heat activated stock solution)).
  • protease and phosphatase inhibitors 150 mMNaCl, 50 ni Tris pH 8.0, 1.0% NP-40, 0.5% deoxycholate, 0.1% sodium dodecy
  • the lysed cells were let sit on ice for 5-15 minutes, the pipetted several times and transferred to microcentrifuge tubes.
  • the cells were fully lysed by carrying out 2 freeze (dry ice) thaw (room temperature) cycles or sonicating the extract on ice for 10 seconds with a probe sonicator, then centrifuged in a Brinkmann mucrocentrifuge at full speed at 4 °C for 15 minutes. The supernatant was removed and transferred to another tube; the protein extract was passed through a 26 gauge needle to completely shear all DNA in the extracts, and the protein concentration was quantitated using Bio-Rad protein assay dye reagent (Bio-Rad Laboratories, catalog #500-0006).
  • the blot was then incubated with the appropriate secondary antibody (HRP conjugated goat anti-rabbit antibodies, Zymed, South San Francisco, CA) at 1:1000 in 0.5% NFDM in TBST for 2 hr at RT, and washed twice with TBST for 15-30 minutes each at room temperature.
  • the blot was developed using ECL (Amersham International) plus Western blotting detection reagents in accordance with the manufacturer's instructions, and exposed to single emulsion Biomax film for 10 seconds to 10 minutes.
  • Receptor Coated Plates Dispense 100 ⁇ L of 10 ⁇ g / mL NeutrAvidin (in 50 mM sodium carbonate, pH9) to Nunc Microsorp 96-well microtiter plates. Incubate overnight at 4°C to coat. Shake out solution and blot excess liquid from the inverted and tapped plate.- Immediately add 200 ⁇ L SuperBlock (Pierce) per well. Shake hard briefly to block upper part of each well, then shake gently for 30 minutes. Again shake out solution and blot. Use a plate washer to rinse all the plates with a single 4 cycle rinse to remove residual avidin (use a program that leaves rinse solution in wells at end).
  • Assay Rinse the receptor coated plates with a single 4 cycle rinse (use a program that leaves rinse solution in wells at end). After a 30 minute pre-incubation of the resuspended compound plates, shake and blot the rinsing solution from one of the receptor coated plates. Transfer 100 ⁇ L from each well of the compound plate to the same well of this receptor coated plate. Repeat for each plate so that the pre-incubation time of the compound solution is the same 30 minutes.

Abstract

L'invention porte sur des analogues de salicylate représentés par la formule I, sur des méthodes de fabrication, sur des compostions pharmaceutiques les contenant et sur des méthodes d'utilisation. Ces composés sont des antagonistes d'interleukine-4 et conviennent au traitement de l'asthme et des allergies.
PCT/US2001/044643 2000-11-28 2001-11-27 Analogues de salicylate utilises en tant qu'antagonistes d'interleukine-4 WO2002044128A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002219920A AU2002219920A1 (en) 2000-11-28 2001-11-27 Salicylate analogs as interleukin-4 antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72478200A 2000-11-28 2000-11-28
US09/724,782 2000-11-28

Publications (2)

Publication Number Publication Date
WO2002044128A2 true WO2002044128A2 (fr) 2002-06-06
WO2002044128A3 WO2002044128A3 (fr) 2003-03-13

Family

ID=24911884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/044643 WO2002044128A2 (fr) 2000-11-28 2001-11-27 Analogues de salicylate utilises en tant qu'antagonistes d'interleukine-4

Country Status (2)

Country Link
AU (1) AU2002219920A1 (fr)
WO (1) WO2002044128A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8019550B2 (en) 2002-07-24 2011-09-13 Keddem Bioscience Ltd. Drug discovery method
US8829041B2 (en) 2006-06-23 2014-09-09 Abbvie Inc. Cyclopropyl amine derivatives
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1266058A (fr) * 1969-07-08 1972-03-08
WO1997043241A1 (fr) * 1996-05-13 1997-11-20 Nippon Shinyaku Co., Ltd. Composes d'ethylene substitue et medicaments
WO1999001127A1 (fr) * 1997-07-03 1999-01-14 Smithkline Beecham Corporation Composes et procedes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1266058A (fr) * 1969-07-08 1972-03-08
WO1997043241A1 (fr) * 1996-05-13 1997-11-20 Nippon Shinyaku Co., Ltd. Composes d'ethylene substitue et medicaments
WO1999001127A1 (fr) * 1997-07-03 1999-01-14 Smithkline Beecham Corporation Composes et procedes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OMU, ALEXANDER E. ET AL: "Effect of antihypertensive therapy in preeclampsia on levels of serum interleukin -4" GYNECOLOGIC AND OBSTETRIC INVESTIGATION (1996), 42(4), 230-236 , 1996, XP008008293 *
TCHERDAKOFF P.: "Side-effects with long-term labetalol: an open study of 251 patients in a single centre" PHARMATHERAPEUTICA., vol. 3, no. 5, 1983, pages 342-348, XP008008752 CLAYTON-WRAY PUBLICATIONS, LONDON., GB ISSN: 0308-051X *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8019550B2 (en) 2002-07-24 2011-09-13 Keddem Bioscience Ltd. Drug discovery method
US9405885B2 (en) 2002-07-24 2016-08-02 Keddem Bioscience Ltd. Drug discovery method
US8829041B2 (en) 2006-06-23 2014-09-09 Abbvie Inc. Cyclopropyl amine derivatives
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives

Also Published As

Publication number Publication date
AU2002219920A1 (en) 2002-06-11
WO2002044128A3 (fr) 2003-03-13

Similar Documents

Publication Publication Date Title
US6376524B1 (en) Triphenyl compounds as interleukin-4 antagonists
US5019588A (en) 1-oxaspiro[4,5] decane-7,8-diaminoarylamides
RU2228927C2 (ru) Производные аминов или амидов, фармацевтическая композиция на их основе и способ антагонизирования рецептора y5 нейропептида npy
US5536736A (en) Triazolyl-phenoxyacetic acid compounds which have useful pharmaceutical utility
US6806279B2 (en) Small-molecule inhibitors of interleukin-2
US6835752B2 (en) Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient
JP3897594B2 (ja) ミクロソームトリグリセリド輸送タンパク質およびアポリポタンパク質分泌の阻害剤として有用なカルボキサミド
JP2014510074A (ja) アンドロゲン受容体アンタゴニストおよびその使用
SK282174B6 (sk) Deriváty hydroxamovej kyseliny, farmaceutický prostriedok s ich obsahom a ich použitie
US5624959A (en) Naphthyloxyacetic acid
KR20090123969A (ko) 여포자극호르몬 조절자로서의 신규의 벤즈아미드 유도체
JP2011508787A (ja) 炎症疾患治療に有用な２−フェニルフェノキシ酢酸
CA2414881A1 (fr) Derives de glutaramide substitues par du cyclopentyl utilises comme inhibiteurs de l'endopeptidase neutre
EP0279466B1 (fr) Dérivés de naphtalène et agents pharmaceutiques antiallergiques et anti-inflammatoires
WO2002044128A2 (fr) Analogues de salicylate utilises en tant qu'antagonistes d'interleukine-4
JP3231775B2 (ja) 心循環器系に作用する２−アミノ−１，２，３，４−テトラヒドロナフタレン誘導体、それらを製造する方法、及びそれらを含む医薬組成物
US5298652A (en) N-substituted glycines, inhibitors of phospholipase A2
JP3901239B2 (ja) アリールアルカン誘導体
EP0557305B1 (fr) Derives de (2-thienyl) alkylamine possedant des proprietes neuroprotectrices
AU6935698A (en) Antiviral protease inhibitors
EP0645374B1 (fr) Compose 5-amino-2-phenoxylsulfonanilide
JPH07215929A (ja) ナフチルオキシ酢酸誘導体およびそれらを有効成分として含有する薬剤
JP2002522497A (ja) Ｃ３ａ受容体リガンド
JP2520318B2 (ja) スルホニルアルキルカルボン酸誘導体
JP2510893B2 (ja) ナフチルスルホニルアルキルカルボン酸誘導体

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP